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Hydroxydihydrobovolide (HDB) was for the first time isolated from Portulaca oleracea L. and then its 
cytotoxicity against SH-SYTY cells was studied. Moreover, a rapid and sensitive ultra-high performance 
liquid chromatographic (UHPLC) method with bergapten as internal standard (IS) was developed and 
validated to investigate the pharmacokinetics of HDB in rats after intravenous and oral administrations 
of extract (POE). The UHPLC analysis was performed on a Diamonsil C18 analytical column, using 
acetonitrile-water (35:65, v/v) as the mobile phase with UV detection at 220 nm. The calibration curve 
was linear over the range of 0.2-25 µg/mL in rat plasma. The average extraction recovery was from 
90.1 to 98.9%, and the relative standard deviations (RSDs) of the intra- and inter-day precisions were 
less than 4.7 and 4.1%, respectively. The results showed that 50 µM HDB had significant cytotoxicity 
on the SH-SY5Y cells, which was rapidly distributed with a Tmax of 11 min after oral administration 
and presented a low absolute bioavailability, 4.12%. 
Uniterms: Portulaca oleracea L./hydroxydihydrobovolide. Portulaca oleracea L./
hydroxydihydrobovolide/cytotoxicity. Portulaca oleracea L./hydroxydihydrobovolide/pharmacokinetics. 
Hydroxydihydrobovolide/Ultra-high performance liquid chromatography.
INTRODUCTION
Portulaca oleracea L., a member of family 
Portulacaceae, with diffusely branched and succulent 
stems, is distributed extensively in temperate and 
tropical regions (Zhu et al., 2009). P. oleracea L., being 
a popular traditional Chinese medicine recorded in the 
Chinese Pharmacopoeia is commonly used for removing 
heat, counteracting toxicity, cooling blood, hemostasia 
and antidysentery (The Pharmacopoeia PRC, 2015). 
Pharmacological studies demonstrated that the plant 
possessed many activities including the neuroprotective 
effect (Ahmed, Moneim, 2013), anti-tumor (Zhao et al., 
2013), anti-inflammatory (Meng et al., 2016), wound-
healing effect (Rashed et al., 2003), antibacterial (Chan 
et al., 2015) and hypocholesterolemic (Movahedian, 
Ghannadi, Vashirnia, 2007).With its popularity, more 
and more scholars thus pay more attention to its bioactive 
components, such as terpenes (Xin et al., 2008), phenolic 
acids and coumarins (Awad, 1994), flavonoids (Xu, Yu, 
Chen, 2006) and alkaloids (Tian et al., 2014). Also, the 
pharmacokinetics of some of the bioactive components 
of P. oleracea L. (Cheng et al., 2012; Zhang et al., 2015) 
was reported recently. 
In the present study, hydroxydihydrobovolide 
(HDB), which belongs to the α-β-unsaturatedγ-lactone 
and presenting potent anti-HIV activity (Zhang et al., 
2005), was for the first time, isolated from Portulaca 
oleracea L. with its pharmacokinetics investigated in rat 
plasma following intravenous and oral administration 
using a rapid and specific UHPLC method, and its absolute 
bioavailability was discussed. In addition, the cytotoxicity 
of HDB on the SH-SY5Y cells was studied. 
MATERIAL AND METHODS
Plant materials and chemicals
The whole herbs of P. oleracea L. were collected 
in Shijiazhuang (Hebei, China) in June 2014, and 
identified by Prof. Tingguo Kang. Voucher specimens 
(No. 20140312) were deposited at School of Pharmacy, 
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Liaoning University of Traditional Chinese Medicine. The 
internal standard (IS), bergapten was provided by Sichuan 
Weikeqi Biological Technology Co., Ltd (Chengdu, 
China) (Figure 1b). Methanol and acetonitrile were all of 
HPLC grade provided by Damao Chemical Reagent Plant 
(Tianjin, China). All other reagents were of analytical 
grade purchased from Jinfeng Chemical Factory (Tianjin, 
China), and the water was purified with Milli-Q® Biocel 
Ultrapure Water System (Millipore, Bedford, MA, USA).
Isolation and identification
A sample (80 kg) of the whole herb of P. oleracea 
L. was extracted with water twice and each for 2 hours. 
The crude extract was then concentrated and passed 
through a porous-polymer resin (AB-8, Tianjin, China), 
eluted with water, 50% and 70% ethanol, successively. 
The fraction of 70% extraction was evaporated under 
reduced pressure to obtain the P. oleracea L. extract 
(POE) of 200 g, and 150 g of the extract was partitioned 
with ethyl acetate, and subsequently evaporated and 
adsorbed on a polyamide resin (80-100 mesh, Taizhou 
LuqiaoSijia Biochemical Plastic Factory, Zhejiang, 
China) column. After eluting with water, as well as 30%, 
50% and 70% ethanol stepwise, the fraction eluted with 
70% ethanol was evaporated and subjected to silica-
gel column chromatography with ethyl acetate and 
methanol as the gradient eluent (10:1, 5:1, 1:1) to obtain 
1-100 fractions, and then the fractions of 70-100 were 
repeatedly subjected to ODS column chromatography 
under medium pressure and eluted with methanol/water 
(70:30, v/v) to obtain 10 fractions. The fractions of 6 
and 7 were purified with Sephadex LH-20 and eluted 
with methanol-water (70:30) to get the pale yellow oil 
compound (16 mg) with the purity checked by UHPLC 
more than 98%. Its molecular formula (C11H18O3) with 3 
degrees of unsaturation was deduced from a protonated 
molecular ion peak at m/z 199.1108 [M + H]+ of HR-ESI-
TOF-MS. 1H-NMR (500 MHz, CDCl3) δ: 1.96 (1H, br, 
H-6a), 1.93 (3H, d, J = 0.75 Hz, H-11), 1.81 (3H, d, J = 
0.85 Hz, H-12), 1.77 (1H, br, H-6b), 1.29 (4H, m, H-8, 
-9), 1.27 (2H, m, H-7), 1.17 (1H, br, OH), 0.88 (3H, t, J 
= 6.3 Hz, H-10); 13C-NMR (100 MHz, CDCl3) δ: 172.18 
(C-2), 157.80 (C-4), 125.28 (C-3), 107.02 (C-5), 35.99 
(C-6), 31.55 (C-7), 22.59 (C-8), 22.42 (C-9), 13.91 (C-
10), 10.69 (C-11), 8.42 (C-12). The 1H NMR, 13C NMR 
and DEPT spectrum showed 11 carbon resonances, 
including three methyls (C-10, -11, -12), four methylenes 
(C-6, -7, -8, -9) and one carbonyl (C-2), two olefinic (C-
3, -4) carbons, and one quaternary carbon. The HMBC 
spectrum showed correlations of H-11/C-3, C-4, C-5, 
C-12, H-12/C-2, C-3, C-4 and C-11, H-10/C-8, C-9; 
H-8, H-9, H-10/C-7, H-8, H-9/C-10, H-8/C-9 or H-9/C-8 
along with the 1H-1H COSY cross-peaks of H-8 and H-9 
with H-10; H-7 with H-10; H-11 with H-12, indicating 
that there is a structure of oxole with methyl substitute 
located at C-3, C-4 and a carbon chain fragment attached 
to the oxole. To satisfy the molecular formula, the 
presence of one hydroxyl, together with the carbon chain 
substituted at C-5, was reasonably arranged considering 
the downfield chemical shift of C-5 (δC 107.02). The 
relative configuration of HDB was established by NOE 
spectrum, which showed the following correlations: 
H-6a with H-6b, H-8, H-9 with H-10, H-11 and H-12, 
H-11 with H-12; H-7 with H-10 and the active hydrogen 
in hydroxy, as shown in Figure 2. Following the above 
evidence, the structure of the compound was confirmed 
as shown in Figure 1a, and 1H NMR (500 MHz, CDCl3) 
and 13C NMR (500 MHz, CDCl3) spectral data were 
listed in Table I. The spectral data were consistent with 
previous report of hydroxydihydrobovolide (Zhang et 
al., 2014b).
Cell culture
SH-SY5Y cells, which were kindly provided by 
Prof. Jingxian Yang (Liaoning University of Traditional 
Chinese Medicine, China), are human neuroblastoma-
derived cell line and have neuron-like characteristic. 
The cells were cultured in DMEM high glucose medium 
(Hyclone, USA) supplemented with 10% fetal bovine 
serum (Zhejiang Tianhang Biotechnology Co., Ltd.) and 
100 U/mL penicillin-streptomycin (Hyclone, USA) at 
37°C with 5% CO2.
FIGURE 2 - 1H-1H COSY, key HMBC and NOESY correlations 
of hydroxydihydrobovolide.
FIGURE 1 - Structures of hydroxydihydrobovolide (a) and 
IS (b).
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Cell viability assay
Cell viability was assayed by CCK-8 (Cell Counting 
Kit-8, Beyotime Co., Ltd., China) according to the 
manufacturer’s instructions (Li, Zhang, Chen, 2008). In 
brief, 1.6 ×104 cells/well of SH-SY5Y were seeded in 96-
well plates and cultured in 100 µL DMEM medium. After 
24 h, the cells were treated with fresh medium containing 
different concentrations of HDB (0.01, 0.1, 1, 10, 50 µM) 
for 48 h, then the cells were washed with PBS three times 
and incubated in 100 µL DMEM medium with 10% CCK-
8 solution. After incubation at 37°C for 2 h, absorbance at 
450 nm was measured with a microplate reader (Mindray, 
China). The cell viability of % control in different 
concentration of HDB was plotted as means ± standard 
deviations (SD) of cell proliferation rate. The data was 
analyzed with One-way ANOVA (SPSS software version 
11.5, SPSS, Chicago, USA), and statistical significance 
was considered at p< 0.05 or p< 0.01.
Chromatographic system and conditions
A Shimadzu UHPLC system (Japan) was equipped 
with a Solvent Delivery Pump (Shimadzu LC-30AD), 
a vacuum degasser (DGU-20A) a Shimadzu UV-VIS 
spectrophotometric detector (SPD-20A) and ChemStation 
software (Shimadzu). Chromatographic separation of 
HDB from the IS was achieved on an analytical column 
(Diamonsil C18, 4.6 mm×150 mm, i.d., 5µm) (Dikma 
Technologies, Bejing, China) connected with a guard 
column (KRC18, 35 × 8.0 mm, i.d., 5 µm), (Dalian 
Create Science and Technology Co., Ltd, Dalian, China). 
The mobile phase for UHPLC analysis consisting of 
acetonitrile-water (35:65, v/v) was passed under vacuum 
through a 0.22µm filter membrane and degassed before 
use. The analysis was carried out at a flow rate of 1 mL/min 
with the detection wavelength set at 220 nm and column 
temperature at 40 °C.
Preparation of calibration standards and quality 
control samples
The stock solutions of HDB and IS were prepared 
in methanol to yield the concentrations of 133 µg/mL 
and 18.2 µg/mL, respectively. The working solutions 
were prepared by diluting stock solution in series to 
concentrations over the range of 0.4-50 µg/mL. All the 
solutions were stored at 4°C before use. Seven calibrators 
(0.2, 0.5, 1.0, 2.0, 4.0, 10.0, and 25.0 µg/mL) of HDB and 
IS were prepared by adding the series of standard working 
solutions of HDB (50 µL) and the IS (0.91 µg/mL, 20µL) 
to 100 µL of drug-free rat plasma. Quality control (QC) 
samples were prepared at three concentrations (low, mid, 
and high) covering the whole range of the calibration 
curve. Low concentration (0.5 µg/mL) was 2.5 times of the 
lower limit of quantification, the high concentration (20 
µg/mL) was 80% of the upper limit of quantification and 
the mid one (4.0 µg/mL) was near the geometric mean of 
them. The whole QC samples were stored at -20 °C until 
analysis.
Animals and blood sampling
Male Wistar rats (250±20 g) were supplied by 
the Laboratory Animal Service Center of Liaoning 
Changsheng Biotechnology Co. Ltd. (Benxi, China). 
They were housed in an environmentally controlled 
breeding room for 1 week before the experiments and 
were fed regular chow with standard laboratory food 
and water ad libitum and fasted 12-16 h prior to the 
experiment. All animal studies were carried out according 
to the requirement of the National Act on the Use of 
Experimental Animal (China) that was approved by 
the Committee of Ethics of Animal Experimentation of 
Liaoning University of Traditional Chinese Medicine. 
For the pharmacokinetics, the two groups of rat (five rats 
per group) were assigned to receive POE solution via 
intravenous at a single dose of 0.75 mL/kg (equivalent 
to 5.9 mg/kg of HDB), and oral administration at a 
dosage of 10 mL/kg (equivalent to 78.9 mg/kg of HDB), 
respectively. Serial blood samples (0.3 mL) were obtained 
via the orbitalis vena at times of 3, 5, 8, 11, 15, 20, 25, 
TABLE  I  -  1H-NMR and  13C-NMR spec t ra l  da ta  o f 
hydroxydihydrobovolide (500 MHz, CDCl3)
Position δC Type δH (J in Hz)
2 172.18 C=O
3 125.28 C
4 157.80 C
5 107.02 C
6 35.99 CH2 1.96 (1H, br, H-6a)
1.77 (1H, br, H-6b)
7 31.55 CH2 1.27 (2H, m)
8 22.59 CH2 1.29 (2H, m)
9 22.42 CH2 1.29 (2H, m)
10 13.91 CH3 0.88 (3H, t, J = 6.3 Hz)
11 10.69 CH3 1.93 (3H, d, J = 0.75 Hz)
12 8.42 CH3 1.81 (3H, d, J = 0.85 Hz)
5 OH 1.17 (1H, br)
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30, 45, 60, 90 min after administration and collected into 
heparinized centrifuge tubes. The blood samples were 
immediately centrifuged at 3,500 g for 15 min at room 
temperature. The plasma sample was stored at -20 °C 
until analysis.
Plasma sample preparation
To 100 µL plasma, 20 µL of IS (0.91 µg/mL) and 
0.5 mL methanol were successively pipetted, followed 
by vortex mixing for 1 min and centrifuging at 3,500 g 
for 15 min to precipitate the protein. The supernatant 
was collected and evaporated to dryness at 40°C under 
a gentle stream of nitrogen. The dried residue was then 
reconstituted with 100 µL mobile phase, and centrifuged 
at 15,000 g for 5 min, and an aliquot (20 µL) of the 
supernatant was injected into the UHPLC system for 
analysis.
Method validation
Selectivity 
The selectivity was determined by comparing 
chromatograms of blank plasma obtained from rats prior 
to dosing with those of corresponding standard plasma 
spiked with HDB and bergapten, and samples from rats 
after administration of POE. 
Linearity, LOD and LOQ
The evaluation of the linearity was performed with 
a seven-point calibration curve over the concentration 
range of 0.2-25 µg/mL. The peak area ratios of the analyte 
with IS were plotted against standard concentrations 
to establish calibration curves for HDB. The slope and 
intercept of the calibration graphs were calculated by 
weighted (1/c2) least squares linear regression. Limit of 
detection (LOD) and limit of quantification (LOQ) via 
diluting the QC samples stepwise were determined by 
S/N=3 and S/N=10 (signal-to-noise ratio), respectively, 
giving an acceptable accuracy (RE) within 20% and a 
precision (RSD) that did not exceed 20%.
Precision and accuracy
The intra-day precision and accuracy were evaluated 
by determining the QC samples at three concentration 
levels with five replicates on the same day, while the 
inter-day values were assessed in the same way on three 
consecutive days. The precision was expressed as RSD, 
which should be less than 15%, except at the LOQ where 
it should not exceed 20%, and the accuracy of the assay 
was determined by comparing the means of the determined 
HDB concentrations with the nominal concentrations. 
The mean percentage deviation from the nominal values 
expressed as RE which should be within ± 15% of the 
nominal value, except at LOQ where it should not exceed 
± 20%.
Extraction recovery
The extraction recoveries of HDB were determined 
by comparing the peak area of QC samples that were at 
low, mid, and high concentrations to that of the unextracted 
standard solutions containing the equivalent amount of 
analytes (n = 6).
Stability
Five aliquots of QC samples at low, mid, and high 
concentrations were prepared for stability assessment.
Unextracted QC samples were subjected to the conditions 
as follows:short-term stability was determined by 
analyzing the QC plasma samples kept at ambient 
temperature (25 °C) for 4 h;long-term stability was 
determined by analyzing the unextracted QC plasma 
samples stored at -20°C for 1 month; freeze-thaw stability 
was investigated after three freeze (-20 °C)-thaw (room 
temperature for 2-3 h) cycles; andpost-preparative 
stability was assessed by analyzing the extracted QC 
plasma samples kept in the autosampler at 4 °C for 12 h. 
These samples were processed and analyzed and the 
concentrations obtained were compared with the nominal 
values of QC samples.
Pharmacokinetics and statistical analysis
Pharmacokinetic analysis of the data was performed 
using both compartmental and non-compartmental 
methods,  wi th  the ass is tance of  DAS program 
(Chinese Pharmacology Society, Beijing, China). The 
compartmental parameters were generated, involving 
apparent volume of distribution at steady state (Vdss), α 
half-life (t1/2α), β half-life (t1/2β), and clearance rate (CL). 
The area under the plasma concentration-time curve 
(AUC0→t) was calculated by the trapezoidal method. The 
area under the plasma concentration-time curve from 
zero to infinity (AUC0→∞) was calculated by means of the 
trapezoidal rule with extrapolation to infinity with terminal 
elimination rate constant. The peak plasma concentration 
(Cmax) and the peak time were directly obtained from the 
drug plasma concentration-time profiles. The terminal 
elimination rate (λz) was estimated by the least-square 
regression analysis of at least last four time points of the 
semi-logarithmic plasma concentration-time curves, the 
terminal half-life (t1/2z) was calculated according to the 
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formula t1/2z =0.693/λz. The mean residence time (MRT) 
was determined by (AUMC)/AUC. AUMC is the area 
under the first momentof the plasma concentration-time 
curve. It is calculated as . The Clearance 
(CL) following dosing was calculated as Dose/AUC0-∞. 
The absolute bioavailability (%) was calculated using the 
following formula:
RESULTS AND DISCUSSION
Effect of HDB on the proliferation of SH-SY5Y 
cells
To investigate the potential protective effect of HDB 
on nerve cells, SH-SY5Y cells were used to evaluate the 
effects on cell proliferation. As shown in Figure 3, after 
exposure to HDB (0.01, 0.1, 1, 10 and 50 µM) for 48 h, the 
cell viability of 1 and 10 µM of HDB slightly decreased, 
but there wasno statistical difference (P>0.05). When the 
concentration of HDB was 50 µM, the cell growth was 
significantly inhibited (P<0.01); while at the concentration 
less than 0.1 µM, HDB did not showsignificant effect 
on SH-SY5Y cells (P>0.05). SH-SY5Y cells have 
dopamine-β-hydroxylase activity, acetylcholinergic, 
glutamatergic and adenosinergic characteristics, so they 
are often used as in vitro models of neuronal function 
and differentiation (Cho, Song, 2014; Ma et al., 2015). 
Meanwhile, SH-SY5Y cells also maintain their cancerous 
nature (Zhang et al., 2014a), and are often used as a human 
neuroblastoma cell line for anti-tumor research. In this 
study, HDB did not show significant neuroprotective or 
promoting proliferation effects when lower than 50 µM, 
but it may have growth-inhibiting orcytotoxic effects in 
SH-SY5Ycells when higher than 50µM. Therefore, HDB 
may have anti-tumor activityat concentrations higher than 
50 µM, its anti-tumor activity and mechanism needfurther 
study with more modelsin vitro or in vivo.
Method development and optimization
In consideration of the poor water-solubility of 
HDB, 10% ethanol was added to prepare the POE solution 
within safety limit for rats. To obtain perfect peak shape, 
suitable retention times and good separation among HDB, 
IS and endogenous substances, the mobile phase was 
chosen after several trials in various proportions with 
methanol-water (40:60-45:55, v/v), acetonitrile-water 
(30:70-40:60, v/v). There wereendogenous substances 
interfering with the determination of analytes when using 
methanol-water systems, and therefore acetonitrile-
water was finally adopted. In addition, to deproteinize 
completely and extract analyte and IS simultaneously, 
acetonitrile and methanol have been tried, respectively; 
methanol was finally chosen because of its low boiling 
point and easy evaporation to dryness and high extraction 
recoveries of analyte and IS. The maximum absorptions 
of HDB at 220 nm were set to be the detection wavelength 
without endogenous interference and it was also found to 
be suitable for the analysis of IS. 
Method validation
To determine the selectivity of this method, blank rat 
plasma, plasma spiked with HDB and IS, plasma samples 
from rats after intravenous and oral doses of POE were 
analyzed (Figure 4). The chromatograms indicated that 
there existed no interfering peaks in the region of the peaks 
of the analyte and IS. The retention times of HDB and IS 
were approximately 13.9 min and 11.1 min, respectively. A 
complete baseline resolution of HDB and IS with adjacent 
peaks was obtained from the chromatogram. The total 
run time was 20.0 min. The regression equation of the 
calibration curves was typically: y = 1.0852x + 0.0320 
(SDslope= 0.044, SDintercept= 0.004) and the linear ranges 
for plasma were within 0.2-25 μg/mL with r = 0.9926. 
The LOD (S/N = 3) and the LOQ (S/N > 10) were 0.045 
and 0.2 μg/mL in plasma, respectively. The RSD of three 
concentrations (0.5, 4.0, 20.0 μg/mL) ranged from 0.9 to 
4.7% for intra-day assay and from 1.6 to 4.1% for inter-
day assay, respectively. The REs of intra- and inter-day 
accuracy were within -1.4 to 6.6%, and the data, which 
conform to the criteria for the analysis of biological 
sample according to guidance of US Food and Drug 
FIGURE 3 - Cytotoxicity of HDB on SH-SY5Y cells. After 
treated with 0.01, 0.1, 1, 10 and 50 µM of HDB for 48 h, cell 
growth was assayed by CCK-8 Kit at 450 nm. Values indicate the 
mean ± SD (n = 6). ****P<0.01 compared to 0.01-10 µM of HDB.
L. Xu, X. Tao, Y. Gao, W. Zhang, Y. Meng, C. Li, M. Jiang, X. Ying
Braz. J. Pharm. Sci. 2017;53(2):e16093Page 6 / 9
Administration (FDA, 2001) were listed in Table II. Mean 
extraction recoveries at three concentration levels for HDB 
ranged from 90.1% to 98.9% suggesting negligible loss 
during extraction. The short-term, long-term and freeze-
thaw stability of HDB in plasma were shown in Table 
III, indicating that no remarkable degradation occurred 
during chromatography, extraction and storage processes 
for plasma samples.
Pharmacokinetic studies
Pharmacokinetic data were processed byDAS 
program (Chinese Pharmacology Society, Beijing, China). 
According to the AkaikeInformation Criterion (AIC) 
and R2, a two-compartment open model (weight=1) 
gave the best fit with the intravenous administration 
and a one-compartment open model (weight=1) for oral 
administration. The plasma concentration-time profile 
was shown in Figure 5, and the mean pharmacokinetic 
parameters of HDB in rats were summarized in Table IV. 
After administration of HDB, HDB can be detected up to 
1.5 hafter both routes. The maximum concentrations in 
plasma after intravenous route (1.300±0.429 µg/mL) was 
about 2.2-fold higher than oral route (0.587 ± 0.13 µg/mL), 
as well as the corresponding AUC0→∞ was 37.22 ± 15.7 
μg·min/mL of intravenous route larger than 20.52 ± 7.69 
μg·min/mL of oral route, suggesting that the intravenous 
route had a higher absorption than oral route. T1/2α to be 
3.67 ± 1.3 min, T1/2β to be 38.69± 13.4 min, the total body 
clearance to be 0.19 ± 0.09 L/kg·min and MRT0→tto be 
25.22 ± 2.99 min after intravenous administration meant 
that HDB presented in an extremely rapid distribution 
and elimination pattern, while HDB was rapidly 
absorbed into blood circulation with peak concentration 
occurring at 11 min after oral administration, and fastly 
eliminated from plasma with t1/2 (29.55 ± 5.46 min), 
MRT0→t (31.72±1.42 min), CL/F (4.40±2.0 L/kg·min), 
suggesting HDB administrated in two routes showed 
a little cumulative phenomenon in the body. In non-
compartmental approach, the CL/Fof i.v. route (0.190 
± 0.093 L/kg·min) is smaller than that of oral route 
(4.402±1.98 L/kg·min), indicating that HDB after 
intravenous administration eliminated slower in the 
blood than oral administration. The apparent volume of 
FIGURE 4 - Representative chromatograms of blank plasma (a), plasma spiked with hydroxydihydrobovolide and IS (b), plasma 
sample 8 min after the intravenous administration (c) and oral administration (d) of hydroxydihydrobovolide. Peak 1: IS; Peak 2: 
hydroxydihydrobovolide.
TABLE II - Precisions, accuracy and recovery of hydroxydihydrobovolide in rat plasma and recovery of hydroxydihydrobovolide 
in rat plasma
Nominal 
Conc. 
(µg/mL)
Intra-day Inter-day
Recovery 
(%)Mean ± SD 
(µg/mL)
RSD 
(%)
RE 
(%)
Mean ± SD 
(µg/mL)
RSD 
(%)
RE 
(%)
0.5 0.53 ± 0.01 1.6 6.5 0.53 ± 0.01 1.6 6.6 90.1 ± 4.4
4.0 3.94 ± 0.19 4.7 -1.4 3.98 ± 0.16 4.1 -0.4 91.4 ± 6.3
20.0 20.41 ± 0.19 0.9 2.0 20.43 ± 0.36 1.8 2.2 98.9 ± 1.5
Intra-day: n = 5; inter-day: n = 3 days with 5 replicates per day; recovery, n = 6
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distribution (Vdss/F=170.25±46.3 L/kg) was relatively 
large after oral administration, suggesting a main 
distribution of HDB in the tissues and organs rather 
than plasma. In contrast, Vdss/F=9.025±2.22L/kg after 
intravenous administration is very small, showing that 
HDB distributed mainly in plasma.The bioavailability of 
HDB can be calculated from the AUCs when administrated 
the extract in the intravenous and oral approaches. That 
is, HDB’s absolute bioavailability after oral dosing of 
Portulaca oleracea L. Extract was 4.12% calculated via 
the formula of (AUCp.o./AUCi.v.)×(Dosei.v./Dosep.o.). Taking 
the absolute bioavailability into account, pharmacokinetic 
parameters (CL, Vdss and terminal t1/2) after i.v. and oral 
dosing were similar (Table IV).The content of HDB in the 
extract was 18.67 mg/g determined by UHPLC method.
CONCLUSION
HDB, being the α-β-unsaturatedγ-lactone that 
possesses the potential bioactivities anti-bacteria (Ordonez 
et al., 2011) and anti-inflammatory (Rungeler et al., 
1999) properties, was first found in P. oleracea L., and 
the effect on cell proliferation and its pharmacokinetics 
were investigated. The result showed that 50 µM HDB 
had cytotoxicity on the SH-SY5Y cells, and HDB could be 
rapidly absorbed and distributed in rats after i.v. and oral 
administrations but with a low absolute bioavailability of 
4.12% following the administration of POE.
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